Anti-OX40L antibodies

US7501496B1 · kind B1 · utility

Assignee

• Roche Palo Alto LLC · US

Inventors

• Joseph Endl · Bad Birnbach, DE
• Elsie M. Eugui · Belmont, US
• Maria Elena Fuentes · Sunnyvale, US
• Yvo Graus · Ede, NL
• Aran Frank Labrijn · Amsterdam, NL
• Martin Lanzendoerfer · Tutzing, DE
• Paul Parren · Utrecht, NL
• Frank Rebers · Utrecht, NL
• Ralf Schumacher · Penzberg, DE
• Stefan Seeber · Penzberg, DE
• Jan Van De Winkel · Utrecht, NL
• Martine Van Vugt · Houten, NL

Key dates

• Filing date: Sep 16, 2005
• Grant date: Mar 10, 2009
• Expiry date: Nov 9, 2025

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/56
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from inflammatory diseases.